Toby M Maher

List of Publications by Year
in descending order

446 papers	21,343 citations	10986 71 h-index	12597 132 g-index
527 all docs	527 docs citations	527 times ranked	15013 citing authors

#	Article	IF	Citations
1	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	27.0	1,025
2	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	5.6	1,006
3	Interstitial Lung Disease in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1248-1254.	5.6	930
4	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	5.6	780
5	Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nature Genetics, 2013, 45, 613-620.	21.4	667
6	The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 906-913.	5.6	453
7	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 147-157.	10.7	410
8	Pulmonary fibrosis secondary to COVID-19: a call to arms?. Lancet Respiratory Medicine,the, 2020, 8, 750-752.	10.7	404
9	Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. European Respiratory Journal, 2012, 40, 377-385.	6.7	335
10	Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. European Respiratory Journal, 2007, 30, 835-839.	6.7	307
11	Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respiratory Medicine,the, 2015, 3, 462-472.	10.7	252
12	Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. Journal of Clinical Investigation, 2009, 119, 2550-63.	8.2	251
13	Shortâ€Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1670-1678.	5.6	247
14	Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?. Trends in Molecular Medicine, 2016, 22, 303-316.	6.7	239
15	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2017, 5, 869-880.	10.7	233
16	Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 435-446.	2.0	226
17	PD-1 up-regulation on CD4 ⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-Î²1 production. Science Translational Medicine, 2018, 10, .	12.4	225
18	Rituximab in severe, treatmentâ€refractory interstitial lung disease. Respirology, 2014, 19, 353-359.	2.3	217

#	Article	IF	Citations
19	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
20	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	5.6	208
21	Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax, 2013, 68, 436-441.	5.6	193
22	Lysophosphatidic Acid Induces Î±vÎ²6 Integrin-Mediated TGF-Î² Activation via the LPA2 Receptor and the Small G Protein GÎ±q. American Journal of Pathology, 2009, 174, 1264-1279.	3.8	192
23	Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax, 2017, 72, 340-346.	5.6	191
24	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	10.7	190
25	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389.	10.7	189
26	Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Science Translational Medicine, 2019, 11, .	12.4	189
27	Significance of connective tissue disease features in idiopathic interstitial pneumonia. European Respiratory Journal, 2012, 39, 661-668.	6.7	184
28	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology, The, 2020, 2, e71-e83.	3.9	182
29	The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax, 2012, 67, 804-810.	5.6	180
30	An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respiratory Medicine,the, 2014, 2, 123-130.	10.7	178
31	Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 208-217.	5.6	177
32	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	5.6	174
33	Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 627-635.	10.7	173
34	Diminished Prostaglandin E₂Contributes to the Apoptosis Paradox in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 73-82.	5.6	170
35	Global incidence and prevalence of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 197.	3.6	170
36	Hostâ€“Microbial Interactions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1640-1650.	5.6	169

#	Article	IF	Citations
37	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory Research, 2019, 20, 205.	3.6	166
38	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2019, 54, 1900161.	6.7	164
39	The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nature Communications, 2019, 10, 6.	12.8	159
40	Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respiratory Research, 2017, 18, 29.	3.6	156
41	Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax, 2016, 71, 701-711.	5.6	153
42	The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Review, 2013, 22, 376-381.	7.1	148
43	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	10.7	145
44	Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 767-776.	5.6	140
45	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	5.6	138
46	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	10.7	137
47	Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. Advances in Therapy, 2018, 35, 724-736.	2.9	134
48	Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, 2020, 55, 1902026.	6.7	134
49	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	10.7	128
50	Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. European Respiratory Journal, 2012, 40, 641-648.	6.7	123
51	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials, 2017, 18, 275.	1.6	121
52	Predicting outcomes in rheumatoid arthritis related interstitial lung disease. European Respiratory Journal, 2019, 53, 1800869.	6.7	121
53	Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax, 2017, 72, 137-147.	5.6	119
54	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	10.7	118

#	Article	IF	Citations
55	Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. Advances in Therapy, 2014, 31, 375-391.	2.9	115
56	Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respiratory Medicine,the, 2017, 5, 857-868.	10.7	115
57	Dynamics of human monocytes and airway macrophages during healthy aging and after transplant. Journal of Experimental Medicine, 2020, 217, .	8.5	113
58	Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81.	5.6	107
59	Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 2002559.	6.7	106
60	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	5.6	102
61	A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1801992.	6.7	101
62	Ambulatory oxygen in interstitial lung disease. European Respiratory Journal, 2011, 38, 987-990.	6.7	99
63	A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 806-815.	10.7	95
64	The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax, 2013, 68, 57-65.	5.6	92
65	Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. European Respiratory Review, 2015, 24, 58-64.	7.1	92
66	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
67	Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genetics, 2016, 17, 74.	2.7	84
68	The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 209-219.	5.6	82
69	Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respiratory Research, 2013, 14, 80.	3.6	81
70	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 2019, 6, e000422.	3.0	79
71	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest, 2020, 158, 646-659.	0.8	79
72	Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Research, 2018, 4, 00084-2018.	2.6	78

#	Article	IF	Citations
73	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	2.0	77
74	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1402-1413.	5.6	77
75	Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respiratory Research, 2019, 20, 148.	3.6	77
76	Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2022, 386, 2178-2187.	27.0	77
77	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	6.7	75
78	Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. , 2015, 152, 18-27.		74
79	Itaconate controls the severity of pulmonary fibrosis. Science Immunology, 2020, 5, .	11.9	73
80	Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700379.	6.7	71
81	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	10.7	71
82	Recent advances in understanding idiopathic pulmonary fibrosis. F1000Research, 2016, 5, 1046.	1.6	66
83	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, 148-153.	5.6	66
84	The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. Pharmacoeconomics, 2018, 36, 779-807.	3.3	66
85	Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 337-342.	6.4	65
86	Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S17-S24.	0.9	65
87	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	10.7	65
88	Translational pharmacology of an inhaled small molecule Î±vÎ²6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 2020, 11, 4659.	12.8	65
89	Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4Âin pulmonary fibrosis. Clinical Science, 2016, 130, 575-586.	4.3	64
90	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	2.6	63

#	Article	IF	Citations
91	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1776-1784.	6.7	61
92	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	6.7	61
93	Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Advances in Bioscience and Biotechnology (Print), 2012, 03, 657-664.	0.7	61
94	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	1.9	60
95	Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 806-815.	6.4	60
96	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	5.6	60
97	Evidence for a Functional Thymic Stromal Lymphopoietin Signaling Axis in Fibrotic Lung Disease. Journal of Immunology, 2013, 191, 4867-4879.	0.8	59
98	Differential Expression of VEGF-A_{xxx} Isoforms Is Critical for Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 479-493.	5.6	58
99	Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment. Clinics in Chest Medicine, 2012, 33, 69-83.	2.1	57
100	Pleuroparenchymal Fibroelastosis. American Journal of Surgical Pathology, 2017, 41, 1683-1689.	3.7	57
101	PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. European Respiratory Review, 2013, 22, 148-152.	7.1	55
102	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration, 2018, 96, 514-524.	2.6	54
103	Pirfenidone in idiopathic pulmonary fibrosis. Drugs of Today, 2010, 46, 473.	1.1	54
104	Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax, 2013, 68, 780-781.	5.6	52
105	Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. Advances in Therapy, 2015, 32, 929-943.	2.9	52
106	Variable utility of mosaic attenuation toÂdistinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1900531.	6.7	52
107	Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. EBioMedicine, 2018, 28, 303-310.	6.1	51
108	The treatment of idiopathic pulmonary fibrosis. F1000prime Reports, 2014, 6, 16.	5.9	50

#	Article	IF	Citations
109	Improved correction for the tissue fraction effect in lung PET/CT imaging. Physics in Medicine and Biology, 2015, 60, 7387-7402.	3.0	48
110	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research, 2018, 5, e000289.	3.0	48
111	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 2017, 8, 48737-48754.	1.8	48
112	Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax, 2022, 77, 829-833.	5.6	47
113	18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 521-528.	6.4	46
114	Personalized medicine in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 470-478.	2.6	46
115	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Annals of the Rheumatic Diseases, 2020, 79, 1478-1484.	0.9	46
116	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	5.6	45
117	Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Design, Development and Therapy, 2012, 6, 261.	4.3	44
118	Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1407-1409.	5.6	43
119	Clinical quantification of the integrin Î±vÎ²6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 967-979.	6.4	43
120	Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 1902442.	6.7	43
121	Enhanced IL-1Î² Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 661811.	4.8	43
122	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	2.6	42
123	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2019, 15, 1009-1017.	3.0	42
124	Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. European Respiratory Journal, 2020, 55, 1901519.	6.7	42
125	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 96, 314-322.	2.6	41
126	The Role of the Lungâ€™s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2019, 20, 5618.	4.1	41

#	Article	IF	Citations
127	A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled Î±vÎ²6 integrin inhibitor. Respiratory Research, 2020, 21, 75.	3.6	41
128	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	5.6	41
129	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	6.7	40
130	The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respiratory Medicine, 2013, 107, 1438-1443.	2.9	39
131	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	2.3	39
132	Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISâ„¢). Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 75-81.	0.8	39
133	King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. European Respiratory Journal, 2019, 54, 1900281.	6.7	37
134	Reproducibility of dynamically represented acoustic lung images from healthy individuals. Thorax, 2008, 63, 542-548.	5.6	35
135	Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Current Opinion in Pulmonary Medicine, 2013, 19, 460-465.	2.6	34
136	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	2.9	34
137	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal, 2020, 56, 1902135.	6.7	34
138	The need for a holistic approach for SSc-ILD â€“ achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	3.6	33
139	Obliterative bronchiolitis in fibreglass workers: a new occupational disease?: TableÂ1. Occupational and Environmental Medicine, 2013, 70, 357-359.	2.8	32
140	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	6.7	32
141	Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2020, 324, 2282.	7.4	32
142	Diffuse Cystic Lung Disease of Unexplained Cause With Coexistent Small Airway Disease. American Journal of Surgical Pathology, 2012, 36, 228-234.	3.7	31
143	The Kingâ€™s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respiratory Research, 2019, 6, e000363.	3.0	30
144	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	2.3	30

#	Article	IF	Citations
145	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal, 2021, 58, 2001518.	6.7	30
146	Biomarker signatures for progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 2022, 59, 2101181.	6.7	30
147	Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23, 593-599.	2.3	29
148	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSISÂ® trials. Respiratory Research, 2020, 21, 36.	3.6	29
149	Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax, 2014, 69, 287-288.	5.6	28
150	A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics, 2017, 35, 479-491.	3.3	28
151	Mixed Ventilatory Defects in Pulmonary Sarcoidosis. Chest, 2020, 158, 2007-2014.	0.8	28
152	Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis. Communications Biology, 2021, 4, 392.	4.4	28
153	Clinical trial research in focus: why do so many clinical trials fail in IPF?. Lancet Respiratory Medicine,the, 2017, 5, 372-374.	10.7	27
154	Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study. Thorax, 2018, 73, 680-682.	5.6	27
155	Management of Fibrosing Interstitial Lung Diseases. Advances in Therapy, 2019, 36, 1518-1531.	2.9	27
156	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208.	5.6	27
157	Provision of home mechanical ventilation and sleep services for England survey: TableÂ1. Thorax, 2013, 68, 880-881.	5.6	26
158	Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis. Respirology, 2018, 23, 498-506.	2.3	26
159	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.8	26
160	Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis. Thorax, 2021, 76, 73-82.	5.6	25
161	Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	5.6	25
162	Vibration Response Imaging Technology in Healthy Subjects. American Journal of Roentgenology, 2008, 191, 845-852.	2.2	24

#	Article	IF	Citations
163	Respiratory microbiome in IPF: cause, effect, or biomarker?. Lancet Respiratory Medicine,the, 2014, 2, 511-513.	10.7	24
164	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	2.6	24
165	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosisâ˜Associated Interstitial Lung Disease: Further Analyses of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2021, 73, 671-676.	5.6	24
166	Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology, 2012, 17, 674-680.	2.3	23
167	Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. European Respiratory Journal, 2019, 54, 1802341.	6.7	22
168	No relevant pharmacokinetic drugâ€“drug interaction between nintedanib and pirfenidone. European Respiratory Journal, 2019, 53, 1801060.	6.7	22
169	Pulmonary fibrosis associated with psychotropic drug therapy: a case report. Journal of Medical Case Reports, 2009, 3, 126.	0.8	21
170	Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis. Scientific Reports, 2018, 8, 1906.	3.3	21
171	The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 25.	3.6	21
172	Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options. Drugs and Aging, 2019, 36, 485-492.	2.7	20
173	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	6.7	20
174	Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study. European Respiratory Journal, 2019, 53, 1801186.	6.7	20
175	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. EBioMedicine, 2021, 69, 103439.	6.1	20
176	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 2021, 8, e001026.	3.0	20
177	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials, 2018, 19, 89.	1.6	19
178	Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. European Respiratory Journal, 2022, 59, 2004587.	6.7	19
179	Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD. Chest, 2022, 161, 728-737.	0.8	19
180	Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 665-666.	5.6	18

#	Article	IF	Citations
181	Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA. Advances in Therapy, 2020, 37, 3292-3298.	2.9	18
182	A Clinical Approach to Diffuse Parenchymal Lung Disease. Immunology and Allergy Clinics of North America, 2012, 32, 453-472.	1.9	17
183	Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Design, Development and Therapy, 2013, 7, 503.	4.3	17
184	Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials, 2017, 18, 201.	1.6	17
185	Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 775-778.	5.6	17
186	DNA Methylome Alterations Are Associated with Airway Macrophage Differentiation and Phenotype during Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 954-966.	5.6	17
187	In search of the fibrotic epithelial cell: opportunities for a collaborative network. Thorax, 2012, 67, 179-182.	5.6	16
188	Immunosuppression for Connective Tissue Diseaseâ€“Related Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 265-273.	2.1	16
189	Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register: TableÂ1. Thorax, 2014, 69, 766-767.	5.6	16
190	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. European Respiratory Journal, 2016, 48, 1524-1526.	6.7	16
191	Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, 16, 927-930.	3.2	16
192	Sarcoidosis in the UK: insights from British Thoracic Society registry data. BMJ Open Respiratory Research, 2019, 6, e000357.	3.0	16
193	Precision medicine in idiopathic pulmonary fibrosis. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 585-587.	0.5	15
194	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	5.6	15
195	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	5.6	15
196	Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARKÂ®trial. BMJ Open Respiratory Research, 2018, 5, e000325.	3.0	14
197	Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Research, 2021, 7, 00405-2021.	2.6	14
198	CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1440-1448.	5.6	14

#	Article	IF	Citations
199	Lost in translation; from animal models of pulmonary fibrosis to human disease. Respirology, 2009, 14, 915-916.	2.3	13
200	The role of precision medicine in interstitial lung disease. European Respiratory Journal, 2022, 60, 2102146.	6.7	13
201	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. Clinical Reviews in Allergy and Immunology, 2022, 63, 472-489.	6.5	13
202	CT Findings of Varicella Pneumonia After Lung Transplantation. American Journal of Roentgenology, 2007, 188, W557-W559.	2.2	12
203	Native Valve Aspergillus Endocarditis Complicating Lung Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 910-913.	0.6	12
204	Incidence of the Pneumoconioses in the United Kingdom General Population between 1997 and 2008. Respiration, 2012, 84, 200-206.	2.6	12
205	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 381, 1595-1597.	27.0	12
206	Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clinical Rheumatology, 2020, 39, 1173-1179.	2.2	12
207	Clinical Utility of Home versus Hospital Spirometry in Fibrotic Interstitial Lung Disease: Evaluation after INJUSTIS Interim Analysis. Annals of the American Thoracic Society, 2022, 19, 506-509.	3.2	12
208	Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 550-562.	5.6	12
209	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	2.9	12
210	Drugâ€‐radiationâ€‐induced interstitial lung disease in the United Kingdom general population: Incidence, allâ€‐cause mortality and characteristics at diagnosis. Respirology, 2012, 17, 861-868.	2.3	11
211	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	6.7	11
212	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Research, 2021, 7, 00235-2020.	2.6	11
213	Shortâ€‐term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis. Respirology, 2022, 27, 202-208.	2.3	11
214	Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. Journal of Clinical Epidemiology, 2015, 68, 1019-1027.	5.0	10
215	Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. Advances in Therapy, 2020, 37, 2460-2476.	2.9	10
216	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092.	5.6	10

#	Article	IF	Citations
217	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders, 2022, 7, 168-178.	1.7	9
218	Vascular density does not predict future metastatic disease in clinical stage 1 nonâ€seminomatous germ cell tumours of the testis. Histopathology, 1998, 32, 217-224.	2.9	8
219	Year in review 2012: Acute lung injury, interstitial lung diseases, sleep and physiology. Respirology, 2013, 18, 555-564.	2.3	8
220	Disease stratification in idiopathic pulmonary fibrosis: the dawn of a new era?. European Respiratory Journal, 2014, 43, 1233-1236.	6.7	8
221	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Respiratory Medicine, 2016, 120, 131-133.	2.9	8
222	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	4.1	8
223	Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. Thorax, 2020, 75, 901-903.	5.6	8
224	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	2.6	8
225	Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis. Thorax, 2023, 78, 551-558.	5.6	8
226	The diagnosis of idiopathic pulmonary fibrosis and its complications. Expert Opinion on Medical Diagnostics, 2008, 2, 1317-1331.	1.6	7
227	Diffuse parenchymal lung disease. Medicine, 2012, 40, 314-321.	0.4	7
228	Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology. Respirology, 2014, 19, 428-437.	2.3	7
229	Update in Interstitial Lung Disease 2016. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 132-138.	5.6	7
230	Regularized Latent Class Model for Joint Analysis of High-Dimensional Longitudinal Biomarkers and a Time-to-Event Outcome. Biometrics, 2019, 75, 69-77.	1.4	7
231	Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial. European Respiratory Journal, 2020, 55, 1901157.	6.7	7
232	Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study. BMJ Open, 2021, 11, e048808.	1.9	7
233	Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 283-284.	5.6	7
234	S11 Pirfenidone Post-authorisation Safety Registry (passport)-interim Analysis Of Ipf Treatment. Thorax, 2014, 69, A8-A9.	5.6	6

#	Article	IF	Citations
235	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution â€“ Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e48.	10.7	6
236	A lesson in plasticity: a 74-year-old man with plastic bronchitis. Thorax, 2017, 72, 1055-1057.	5.6	6
237	Can monocytes predict prognosis of idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2019, 7, 467-469.	10.7	6
238	Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 58, 2100172.	6.7	6
239	Measurement of hypoxia in the lung in IPF: an F-MISO PET CT study. European Respiratory Journal, 2021, 58, 2004584.	6.7	6
240	Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. , 2015, , .		6
241	PAciFy Coughâ€”a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough. Trials, 2022, 23, 184.	1.6	6
242	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Advances in Therapy, 2022, 39, 1081-1095.	2.9	6
243	Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology, 2023, 62, SI43-SI53.	1.9	6
244	Genome-wide Enrichment of TERT Rare Variants in IPF Patients of Latino Ancestry. American Journal of Respiratory and Critical Care Medicine, 0, , .	5.6	6
245	P272â€…Epidemiology of idiopathic pulmonary fibrosis in the uk: findings from the british lung foundationâ€™s â€˜respiratory health of the nationâ€™ project. Thorax, 2016, 71, A236.1-A236.	5.6	5
246	Towards a global initiative for fibrosis treatment (GIFT). ERJ Open Research, 2017, 3, 00106-2017.	2.6	5
247	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. Respirology, 2020, 25, 1274-1282.	2.3	5
248	Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1030-1032.	5.6	5
249	A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey. , 2018, , .		5
250	Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis. , 2019, , .		5
251	Sildenafil in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2010, 363, 2169-2171.	27.0	4
252	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. Clinical Pulmonary Medicine, 2011, 18, 257-264.	0.3	4

#	Article	IF	Citations
253	Primary Endpoints in Phase 3 Clinical Trials in Idiopathic Pulmonary Fibrosis: One Step at a Time. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1271-1272.	5.6	4
254	Exercise-induced haemoptysis: a thoroughbred cause?. Thorax, 2013, 68, 599-600.	5.6	4
255	P18â€…Idiopathic pulmonary fibrosis survival has not improved in the 21st century; analysis of CPRD gold primary care data. Thorax, 2013, 68, A82.2-A83.	5.6	4
256	Detecting anxiety and depression in patients diagnosed with an interstitial lung disease. Can we do better?. Respirology, 2014, 19, 1095-1096.	2.3	4
257	New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e31-e32.	10.7	4
258	UK trainee experience in interstitial lung disease: results from a British Thoracic Society survey. Thorax, 2015, 70, 183-183.	5.6	4
259	Blood-based Diagnosis of Idiopathic Pulmonary Fibrosis. Fantasy or Reality?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1182-1184.	5.6	4
260	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. Advances in Therapy, 2019, 36, 3059-3070.	2.9	4
261	Patient reported distress can aid clinical decision making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohort. European Respiratory Journal, 2019, 53, 1801925.	6.7	4
262	OP0064â€…EVIDENCE-BASED CONSENSUS RECOMMENDATIONS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS. , 2019, , .		4
263	European consensus statements for interstitial lung disease in systemic sclerosis â€“ Authors' reply. Lancet Rheumatology, The, 2020, 2, e319-e320.	3.9	4
264	Pirfenidone post-authorization safety registry (PASSPORT) update. , 2015, , .		4
265	Nintedanib in idiopathic pulmonary fibrosis. Drugs of Today, 2015, 51, 345.	1.1	4
266	If it was good enough for Aristotle..... Thorax, 2011, 66, 183-1184.	5.6	3
267	S38â€…The role of the respiratory microbiome in Idiopathic pulmonary fibrosis. Thorax, 2013, 68, A22.1-A22.	5.6	3
268	Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease. Respirology, 2015, 20, 834-845.	2.3	3
269	Cough in fibrotic lung disease: <scp>A</scp>n unresolved challenge. Respirology, 2017, 22, 1491-1492.	2.3	3
270	Improved quantitation and reproducibility in multi-PET/CT lung studies by combining CT information. EJNMMI Physics, 2018, 5, 14.	2.7	3

#	Article	IF	Citations
271	Chronic hypersensitivity pneumonitis; an enigmatic and frequently fatal disease. European Respiratory Review, 2020, 29, 200177.	7.1	3
272	Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but not Forgotten. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1010-1011.	5.6	3
273	The King's brief interstitial lung disease (K-BILD) questionnaire; an updated minimal important difference. , 2016, , .		3
274	Serum KL-6 as a marker of disease progression in SSc-ILD. , 2018, , .		3
275	Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. , 2019, , .		3
276	Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil. , 2019, , .		3
277	Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial. , 2019, , .		3
278	Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD). , 2019, , .		3
279	Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial. , 2019, , .		3
280	Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial. , 2020, , .		3
281	Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework. Advances in Therapy, 2022, 39, 1045-1054.	2.9	3
282	Diffuse parenchymal lung disease. Medicine, 2008, 36, 265-272.	0.4	2
283	Idiopathic pulmonary fibrosisâ€related pulmonary hypertension; an exercising diagnosis?. Respirology, 2011, 16, 381-383.	2.3	2
284	Successful treatment of progressive diffuse PEComatosis. European Respiratory Journal, 2012, 40, 1578-1580.	6.7	2
285	S98â€…Early Clinical Experience with Pirfenidone For Idiopathic Pulmonary Fibrosis (IPF) in the UK: Interim Results from a UK Cohort. Thorax, 2012, 67, A48.2-A49.	5.6	2
286	P9â€…Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis â€“ initial clinical experience in a UK cohort. Thorax, 2015, 70, A78.2-A78.	5.6	2
287	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2015, 1, 1-18.	2.2	2
288	M30â€…Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials. , 2017, , .		2

#	Article	IF	Citations
289	Rapidly Progressive Cystic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 264-264.	5.6	2
290	S77â€…The idiopathic pulmonary fibrosis patients reported outcome measure (IPF-PROM) is reliable and valid for use in populations with IPF. , 2018, , .		2
291	Gazing into the crystal ball: can treatment response be predicted in IPF?. Lancet Respiratory Medicine,the, 2018, 6, 570-572.	10.7	2
292	Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use. PharmacoEconomics - Open, 2019, 3, 81-91.	1.8	2
293	Anxiety and depression in idiopathic pulmonary fibrosis (IPF): prevalence and clinical correlates. , 2017, , .		2
294	mTOR signalling is an essential pathway for TGF-Î²1induced collagen synthesis. , 2015, , .		2
295	Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort. , 2016, , .		2
296	Late Breaking Abstract - Idiopathic Pulmonary Fibrosis â€“ a worldwide review of â€˜realâ€™ lifeâ€™ practice: experience from a treatment feasibility review in 41 countries. , 2018, , .		2
297	Traction bronchiectasis and platythorax on computed tomography are determinants of progression and mortality in pleuro-parenchymal fibroelastosis. , 2018, , .		2
298	Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease. , 2018, , .		2
299	Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avÃŸ6 integrin inhibitor. , 2019, , .		2
300	Adherence to home spirometry among patients with IPF: results from the INMARK trial. , 2019, , .		2
301	Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?. , 2020, , .		2
302	Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Frontiers in Medicine, 0, 9, .	2.6	2
303	Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 255-256.	5.6	1
304	Year in review 2009: Interstitial lung diseases, acute injury, sleep, physiology, imaging and bronchoscopic intervention. Respirology, 2010, 15, 172-181.	2.3	1
305	P113â€…Secreted Lysyl Oxidase is Elevated in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis. Thorax, 2012, 67, A111.2-A111.	5.6	1
306	Year in review 2011: Acute lung injury, interstitial lung diseases, physiology, sleep and lung cancer. Respirology, 2012, 17, 554-562.	2.3	1

#	Article	IF	Citations
307	S50â€...Hypersensitivity pneumonitis complicated by pulmonary hypertension; patient characteristics and response to targeted therapy: Abstract S50 Table 1.. Thorax, 2013, 68, A27.2-A28.	5.6	1
308	S136 Mtor Signalling Is An Essential Pathway For Tgf-Â1 Induced Âsma And Collagen Gene Expression. Thorax, 2014, 69, A73-A73.	5.6	1
309	Case-based discussion from the Royal Devon and Exeter NHS Foundation Trust: a painful paradox. Thorax, 2014, 69, 779-781.	5.6	1
310	M272 Estimated Cost And Payment By Results (pbr) Tariff Reimbursement For Idiopathic Pulmonary Fibrosis Services Across 14 Specialist Providers In England. Thorax, 2014, 69, A222-A225.	5.6	1
311	Pirfenidone Post-Authorization Safety Registry (PASSPORT): Update and Concomitant Use of NAC and/or Corticosteroids. Chest, 2015, 148, 364A.	0.8	1
312	Transcriptional phenotyping of fibrotic lung disease: a new gold standard?. Lancet Respiratory Medicine,the, 2015, 3, 423-424.	10.7	1
313	P248â€...Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of fvc percent predicted. Thorax, 2016, 71, A222.2-A223.	5.6	1
314	P161â€...Unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF) â€“ insights from patient chart review in five european countries. Thorax, 2016, 71, A171-A172.	5.6	1
315	P168â€...Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states. Thorax, 2016, 71, A175.1-A175.	5.6	1
316	Nintedanib Cost-Effectiveness In Idiopathic Pulmonary Fibrosis In The UK. Value in Health, 2016, 19, A553.	0.3	1
317	Reply: Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1034-1035.	5.6	1
318	S17â€...The burden of idiopathic pulmonary fibrosis in the united kingdom: a retrospective, matched cohort study. Thorax, 2016, 71, A12.1-A12.	5.6	1
319	S98â€...Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis (IPF) under pirfenidone treatment. Thorax, 2016, 71, A58.1-A58.	5.6	1
320	Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?. European Respiratory Journal, 2017, 50, 1701403.	6.7	1
321	Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S3-S4.	0.9	1
322	M19â€...Differences in patient and physician viewpoints of the management of idiopathic pulmonary fibrosis (ipf). , 2017, , .		1
323	P164â€...Cyclophosphamide for the treatment of refractory chronic hypersensitivity pneumonitis. , 2018, , .		1
324	Reply. Arthritis and Rheumatology, 2021, 73, 2354-2355.	5.6	1

#	Article	IF	Citations
325	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-110.	0.7	1
326	Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?. Annals of the American Thoracic Society, 2021, 18, 1285-1286.	3.2	1
327	Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF). , 2017, , .		1
328	LATE-BREAKING ABSTRACT: Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF). , 2015, , .		1
329	A comparison of two scoring methods for the King's brief interstitial lung disease questionnaire. , 2015, , .		1
330	Application of a predictive formula for hypoxic challenge testing in patients with interstitial lung disease. , 2018, , .		1
331	Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and prognosis. , 2018, , .		1
332	Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial. , 2019, , .		1
333	Using a selective avÃŸ6 PET ligand to optimise early phase IPF clinical trials. , 2019, , .		1
334	Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD). , 2019, , .		1
335	Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial. , 2019, , .		1
336	Effect of baseline composite physiologic index on benefit of nintedanib in IPF. , 2016, , .		1
337	First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry. , 2016, , .		1
338	Four metre gait speed (4MGS) predicts mortality and hospitalisation in IPF. , 2018, , .		1
339	Serum biomarkers in SSc-ILD: association with presence, severity and prognosis. , 2019, , .		1
340	Perspectives for the future. , 0, , 260-274.		1
341	Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease. ERJ Open Research, 2022, 8, 00481-2021.	2.6	1
342	Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. , 2020, , .		1

#	Article	IF	Citations
343	Inflammasome activation in airway macrophages and the lung microbiome in IPF. , 2020, , .		1
344	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. , 2020, , .		1
345	Biomarkers for Interstitial Lung Abnormalities; A Stepping-stone Towards IPF Prevention?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	1
346	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respiratory Research, 2022, 23, .	3.6	1
347	Acute breathlessness. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, M40-M43.	0.5	0
348	Vibration Response Imaging Correlates With Air Flow Measured By Spirometry. , 2010, , .		0
349	Rituximab Therapy In Severe Interstitial Lung Disease. , 2011, , .		0
350	Is Smoking Implicated In The Pathogenesis Of Lung Involvement In Systemic Sclerosis?. , 2011, , .		0
351	Year in review 2010: Interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer. Respirology, 2011, 16, 553-563.	2.3	0
352	The Diagnosing and Staging of Idiopathic Pulmonary Fibrosis. Clinical Pulmonary Medicine, 2012, 19, 254-261.	0.3	0
353	S101â€…Intensive Care Unit Admission Should Play a Role in the Management of Selected Patients with Interstitial Lung Disease. Thorax, 2012, 67, A50.1-A50.	5.6	0
354	S68â€…Bioavailability of VEGF in Idiopathic Pulmonary Fibrosis. Thorax, 2012, 67, A34.2-A34.	5.6	0
355	P201â€…Rituximab as rescue therapy in interstitial lung disease refractory to conventional immunosuppression. Thorax, 2013, 68, A167.1-A167.	5.6	0
356	P141â€…Differential expression of conventional and inhibitory VEGFA isoforms in normal and fibrotic fibroblastsâ€“a potential role in IPF pathogenesis?. Thorax, 2013, 68, A139.2-A140.	5.6	0
357	P23 Target And Biomarker Discovery For Hedgehog Pathway Activity In Idiopathic Pulmonary Fibrosis In Support Of A Phase 2 Randomised, Double-blind, Placebo-controlled Study To Assess Efficacy And Safety Of Vismodegib In Ipf (island). Thorax, 2014, 69, A87-A87.	5.6	0
358	P280 Extended Clinical Experience With Pirfenidone During A Named Patient Programme For Idiopathic Pulmonary Fibrosis (ipf): Interim Results. Thorax, 2014, 69, A196-A196.	5.6	0
359	M266 Development Of An Idiopathic Pulmonary Fibrosis (ipf) Patient Reported Outcome Measure (prom): An Iterative Approach To Item Generation. Thorax, 2014, 69, A219-A220.	5.6	0
360	P12â€…Pirfenidone post-authorisation safety registry (PASSPORT) â€“ update and concomitant use of N-acetylcysteine and/or corticosteroids. Thorax, 2015, 70, A79.3-A80.	5.6	0

#	Article	IF	Citations
361	P33â€…Rituximab as rescue therapy in advanced progressive systemic sclerosis associated interstitial lung disease. Thorax, 2015, 70, A92.2-A92.	5.6	0
362	S45â€…MUC5B Genotype does not influence cough severity in IPF. Thorax, 2015, 70, A29.1-A29.	5.6	0
363	S107â€…Disease progression modelling in idiopathic pulmonary fibrosis: a prediction of time to disease progression and life expectancy with pirfenidone. Thorax, 2015, 70, A61-A61.	5.6	0
364	P10â€…Effect of Pirfenidone on gas transfer in patients with idiopathic pulmonary fibrosis. Thorax, 2015, 70, A79.1-A79.	5.6	0
365	P4â€…Patient and Carer Co-investigators: Shared experiences of a Research Steering Group from the Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF-PRoM) study: Abstract P4 Table 1. Thorax, 2015, 70, A76-A77.	5.6	0
366	P32â€…Role of non acid and proximal reflux in scleroderma-associated interstitial lung disease. Thorax, 2015, 70, A92.1-A92.	5.6	0
367	P273â€…Baseline characteristics of patients with idiopathic pulmonary fibrosis aged over 80 years old. Thorax, 2016, 71, A236.2-A237.	5.6	0
368	P062 <break /> The Role of the Fungal Microbiome in IPF. QJM - Monthly Journal of the Association of Physicians, 2016, , .	0.5	0
369	S51â€…MTOR regulates TGF-Î² induced pro-fibrotic gene expression in primary human lung fibroblasts. Thorax, 2016, 71, A31.1-A31.	5.6	0
370	Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of Composite Physiologic Index at Baseline in the INPULSIS Trials. Chest, 2016, 150, 539A.	0.8	0
371	Medicine and Me: a breath of fresh air for IPF. Lancet Respiratory Medicine,the, 2016, 4, 615-616.	10.7	0
372	S56â€…The impact of azithromycin in idiopathic pulmonary fibrosis. , 2017, , .		0
373	M28â€…Deferring treatment with pirfenidone results in loss of lung function that is not recovered by later treatment initiation. , 2017, , .		0
374	S57â€…Predictors of uptake of ambulatory oxygen on completion of the ambox trial, a study to assess effects of ambulatory oxygen on quality of life in patients with fibrotic interstitial lung disease. , 2017, , .		0
375	S34â€…The effects of a novel formulation of inhaled cromolyn sodium (pa101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, controlled, phase 2 trial. , 2017, , .		0
376	S143â€…Serum CYFRA 21â€“1 as a prognostic marker in scleroderma-associated interstitial lung disease. , 2018, , .		0
377	S145â€…Measures of oesophageal impedance are not predictive of lung function decline in interstitial lung disease. , 2018, , .		0
378	S144â€…Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features. , 2018, , .		0

#	Article	IF	Citations
379	P157â€…Hiatus hernia is highly prevalent in idiopathic pulmonary fibrosis and impacts disease progression. , 2018, , .		0
380	Could quality be the key in connective tissue diseaseâ€associated interstitial lung disease?. Respirology, 2018, 23, 801-802.	2.3	0
381	SP0199â€…CASE 2 DISCUSSANT: HOW TO TREAT DIFFICULT ILD. , 2019, , .		0
382	P10â€…Weight loss is a feature of progressive disease in idiopathic pulmonary fibrosis. , 2019, , .		0
383	OP0242â€…SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS. , 2019, , .		0
384	OP0017â€…NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSCIS TRIAL. , 2019, , .		0
385	FRI0301â€…GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL. , 2019, , .		0
386	P7â€…The safety of bronchoalveolar lavage in patients with idiopathic pulmonary fibrosis. , 2019, , .		0
387	S69â€…Verification of genetic associations with scleroderma associated interstitial lung disease. , 2019, , .		0
388	A Transcriptomic Profile of the Proximal Airway Epithelial-Immune Niche in Idiopathic Pulmonary Fibrosis. , 2020, , .		0
389	Current and Emerging Treatment Options in Interstitial Lung Disease. , 2014, , 193-216.		0
390	Response of the King's brief interstitial lung disease (KBILD) questionnaire to pulmonary rehabilitation (PR). , 2015, , .		0
391	A comparison of two scoring methods for the King's sarcoidosis questionnaire. , 2015, , .		0
392	Optimal use of gas transfer values in detecting pulmonary vascular involvement in sarcoidosis. , 2015, , .		0
393	LSC Abstract â€“ Changes in the respiratory microbiome during acute exacerbations of Idiopathic Pulmonary Fibrosis. , 2015, , .		0
394	Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods. , 2015, , .		0
395	LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF). , 2015, , .		0
396	Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms. , 2015, , .		0

#	Article	IF	Citations
397	Sarcoidosis in the UK: Insights from the BTS interstitial lung disease registry. , 2016, , .		0
398	Randomised controlled, crossover trial to evaluate the effects of ambulatory oxygen on health status in patients with fibrotic lung disease. , 2016, , .		0
399	Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF). , 2016, , .		0
400	Development of pre-admission information for referrals with suspected interstitial lung disease to a specialist unit. , 2016, , .		0
401	Rituximab in severe, progressive interstitial lung disease. , 2016, , .		0
402	No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib. , 2016, , .		0
403	Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF). , 2016, , .		0
404	The reliability and validity of the 4 metre gait speed (4MGS) in idiopathic pulmonary fibrosis (IPF). , 2016, , .		0
405	AmbOx trial: does ambulatory oxygen improve quality of life in patients with fibrotic interstitial lung disease?. , 2017, , .		0
406	Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry. , 2017, , .		0
407	Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?. , 2017, , .		0
408	Distinct metabolic alterations in airway macrophages during pulmonary fibrosis. , 2018, , .		0
409	Upper and lower limb muscle strength in idiopathic interstitial pneumonias (IIP). , 2018, , .		0
410	Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study. , 2018, , .		0
411	Lung cysts in pulmonary alveolar proteinosis.. , 2018, , .		0
412	Validity and responsiveness of the Euro-Qol-5 Dimensions-5 Levels (EQ5D5L) in IPF. , 2018, , .		0
413	Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study. , 2018, , .		0
414	Pulmonary function trends predict mortality in patients with hypersensitivity pneumonitis. , 2018, , .		0

#	Article	IF	Citations
415	S76â€…Pleuro-parenchymal fibroelastosis: traction bronchiectasis and extent of platythorax on computed tomography are determinants of disease progression and mortality. , 2018, , .		0
416	Verification of genetic associations with Scleroderma associated Interstitial Lung Disease. , 2019, , .		0
417	Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) â€“ modelling the myth. , 2019, , .		0
418	Decline in 4-metre gait speed (4MGS) over 6 months is associated with mortality in IPF. , 2019, , .		0
419	Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF). , 2019, , .		0
420	Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD). , 2019, , .		0
421	S86â€…Serum biomarkers in SSc-ILD: association with presence, severity and prognosis. , 2019, , .		0
422	P52â€…Vitamin D deficiency is associated with adverse survival in patients with idiopathic pulmonary fibrosis. , 2019, , .		0
423	T3â€…Itaconate drives the resolution of pulmonary fibrosis. , 2019, , .		0
424	T1â€…Meta-analysis of idiopathic pulmonary fibrosis genome-wide analyses identifies three novel genetic signals associated with disease susceptibility. , 2019, , .		0
425	P60â€…Temporally close presentation of primary lung cancer and idiopathic pulmonary fibrosis (IPF): an analysis of incident IPF cases from 2007 â€“ 2018. , 2019, , .		0
426	Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study*. , 2020, 74, .		0
427	Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*. Pneumologie, 2020, 74, .	0.1	0
428	Dose adjustments in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*. , 2020, 74, .		0
429	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial*. , 2020, 74, .		0
430	MUC2MUC5B and TOLLIP variants: no association with disease progression and survival in an IPF cohort. , 2020, , .		0
431	Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial*. , 2020, 74, .		0
432	Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial*. , 2020, 74, .		0

#	Article	IF	Citations
433	Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS Trial*. , 2020, 74, .		0
434	Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial*. , 2020, 74, .		0
435	Monocyte count and decline in forced vital capacity (FVC) in patients with IPF. , 2020, , .		0
436	Modelling IPF-associated chronic cough: role for oxidative stress?. , 2020, , .		0
437	Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD). , 2020, , .		0
438	Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function. , 2020, , .		0
439	Sarcoidosis-associated Pulmonary Hypertension: A London Cohort. , 2020, , .		0
440	Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype. , 2020, , .		0
441	Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial. , 2020, , .		0
442	Pirfenidone in unclassifiable ILD (uILD): subgroup analysis of patients with/without a surgical lung biopsy (SLB). , 2020, , .		0
443	Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs). , 2020, , .		0
444	Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR). , 2020, , .		0
445	Fatum inexorabile â€“ Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?!. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
446	Reply to: The Need for a CYFRA 21-1 Cut-off Value to Predict Clinical Progression of IPF in Clinical Practice. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0